Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.
Dans MG, Boulet C, Watson GM, Nguyen W, Dziekan JM, Evelyn C, Reaksudsan K, Mehra S, Razook Z, Geoghegan ND, Mlodzianoski MJ, Goodman CD, Ling DB, Jonsdottir TK, Tong J, Famodimu MT, Kristan M, Pollard H, Stewart LB, Brandner-Garrod L, Sutherland CJ, Delves MJ, McFadden GI, Barry AE, Crabb BS, de Koning-Ward TF, Rogers KL, Cowman AF, Tham WH, Sleebs BE, Gilson PR
Malaria
Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein.
Nguyen W, Boulet C, Dans MG, Loi K, Jarman KE, Watson GM, Tham WH, Fairhurst KJ, Yeo T, Fidock DA, Wittlin S, Chowdury M, de Koning-Ward TF, Chen G, Yan D, Charman SA, Baud D, Brand S, Jackson PF, Cowman AF, Gilson PR, Sleebs BE
Malaria
The dual action of human antibodies specific to Plasmodium falciparum PfRH5 and PfCyRPA: Blocking invasion and inactivating extracellular merozoites.
Weiss GE, Ragotte RJ, Quinkert D, Lias AM, Dans MG, Boulet C, Looker O, Ventura OD, Williams BG, Crabb BS, Draper SJ, Gilson PR
Malaria
Advances in Plasmodium research, an update: Highlights from the Malaria in Melbourne 2021 conference.
Adderley J, Boulet C, McCann K, McHugh E, Ioannidis LJ, Yeoh LM
Structure of the Pf12 and Pf41 heterodimeric complex of <i>Plasmodium falciparum</i> 6-cysteine proteins.
Dietrich MH, Chan LJ, Adair A, Boulet C, O'Neill MT, Tan LL, Keremane S, Mok YF, Lo AW, Gilson P, Tham WH